SARS-CoV-2 infection in patients with primary central nervous system lymphoma

Laurenge, Alice; Ursu, Renata; Houillier, Caroline; Abdi, Basma; Tebano, Gianpiero; Quemeneur, Cyril; Choquet, Sylvain; Di Blasi, Roberta; Lozano, Fernando; Morales, Andrea; Durán-Peña, Alberto; Sirven-Villaros, Lila; Mathon, Bertrand; Mokhtari, Karima; Bielle, Franck; Martin-Duverneuil, Nadine; Delattre, Jean-Yves; Marcelin, Anne-Geneviève; Pourcher, Valérie; Alentorn, Agusti; Idbaih, Ahmed; Carpentier, Antoine F.; Leblond, Véronique; Hoang-Xuan, Khê; Touat, Mehdi

BACKGROUND: Cancer patients may be at higher risk for severe coronavirus infectious disease-19 (COVID-19); however, the outcome of Primary Central Nervous System Lymphoma (PCNSL) patients with SARS-CoV-2 infection has not been described yet. METHODS: We conducted a retrospective study within the Lymphomes Oculo-Cérébraux national network (LOC) to assess the clinical characteristics and outcome of SARS-CoV-2 infection in PCNSL patients (positive real-time polymerase chain reaction of nasopharyngeal swab or evocative lung computed tomography scan). We compared clinical characteristics between patients with severe (death and/or intensive care unit admission) and mild disease. RESULTS: Between March and May 2020, 13 PCNSL patients were diagnosed with SARS-CoV-2 infection, 11 (85%) of whom were undergoing chemotherapy at the time of infection. The mortality rate was 23% (3/13), and two additional patients (15%) required mechanical ventilation. Two patients (15%) had no COVID-19 symptoms. History of diabetes mellitus was more common in severe patients (3/5 vs 0/8, p = 0.03). Two patients recovered from COVID-19 after mechanical ventilation during more than two weeks and resumed chemotherapy. In all, chemotherapy was resumed after COVID-19 recovery in nine patients (69%) after a median delay of 16 days (range 3–32), none of whom developed unusual chemotherapy complication nor SARS-Cov2 reactivation. CONCLUSION: This preliminary analysis suggests that, while being at higher risk be for severe illness, PCNSL patients with COVID-19 might be treated maximally especially if they achieved oncological response at the time of SARS-CoV-2 infection. Chemotherapy might be resumed without prolonged delay in PCNSL patients with COVID-19. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s00415-020-10311-w) contains supplementary material, which is available to authorized users.